This chapter explores the potential downfall of 23andMe, discussing the risks of false positives in genetic testing, concerns over data security and privacy, and the challenges of becoming a drug maker. It also highlights investors' reluctance to invest further in the company and the uncertainty surrounding its future.
In today’s episode for 6th February 2024, we explore how a once high-flying health tech company is on the verge of getting chucked out of the NASDAQ index.
If you're a person who is great at communicating and are enthusiastic to join our team, Ditto is looking to recruit new Insurance advisors. You don't even have to know about Insurance, we'll train you from scratch and you can enjoy working remotely with a great team. If you're interested in this or know someone who is please click this link. https://bit.ly/48WX5za